ELRANATAMAB-BCMM: 570 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

570

Total FAERS Reports

120 (21.1%)

Deaths Reported

168

Hospitalizations

570

As Primary/Secondary Suspect

Life-Threatening

Disabilities

First Report: 20211108 · Latest Report: 20250922

What Are the Most Common ELRANATAMAB-BCMM Side Effects?

#1 Most Reported

Cytokine release syndrome

115 reports (20.2%)

#2 Most Reported

Death

51 reports (8.9%)

#3 Most Reported

Pyrexia

46 reports (8.1%)

Side Effect	Reports	% of Total	Deaths	Hosp.
Cytokine release syndrome	115	20.2%	22	48
Death	51	9.0%	51	4
Pyrexia	46	8.1%	7	17
Fatigue	31	5.4%	1	14
Neoplasm progression	31	5.4%	9	7
Cytomegalovirus infection reactivation	29	5.1%	1	4
Malignant neoplasm progression	27	4.7%	14	8
Off label use	27	4.7%	2	10
Immune effector cell-associated neurotoxicity syndrome	26	4.6%	6	15
Infection	25	4.4%	13	8
Cytomegalovirus infection	20	3.5%	3	13
Diarrhoea	20	3.5%	2	11
Pneumonia	20	3.5%	8	10
Skin exfoliation	20	3.5%	0	1
Rash	18	3.2%	3	5
Decreased appetite	17	3.0%	2	10
Hypotension	15	2.6%	0	7
Neutropenia	15	2.6%	2	3
Plasma cell myeloma	15	2.6%	10	5
Covid-19	14	2.5%	4	2

Gender: 49.4% female, 50.6% male. Average age: 69.5 years. Most reports from: JP. View detailed demographics →

Year	Reports	Deaths	Hosp.
2021	2	1	1
2023	10	1	2
2024	164	32	73
2025	145	28	54

Indication	Reports
Plasma cell myeloma	239
Plasma cell myeloma refractory	75

Official prescribing information from the FDA-approved drug label.